Jacques B de Kok
- Molecular Biology top 10%
- Cancer Research top 5%
- Pulmonary and Respiratory Medicine top 10%
- Surgery
- Oncology
- Co-authors
- Dorine W. SwinkelsRian RoelofsB. GiesendorfJack A. SchalkenLambertus A. KiemeneyTilly AaldersPaul N. SpanDaphne Hessels
- Topics
- Bladder and Urothelial Cancer Treatments (9 papers)Cancer Research and Treatments (5 papers)Telomeres, Telomerase, and Senescence (5 papers)
- Partner nations
- NetherlandsUnited StatesSweden
In The Last Decade
Jacques B de Kok
24 papers receiving 1.6k citations
Peers
Comparison fields: 5 of 103
- Molecular Biology 962
- Cancer Research 530
- Pulmonary and Respiratory Medicine 362
- Surgery 274
- Oncology 194
Countries citing papers authored by Jacques B de Kok
This map shows the geographic impact of Jacques B de Kok's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacques B de Kok with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacques B de Kok more than expected).
Fields of papers citing papers by Jacques B de Kok
This network shows the impact of papers produced by Jacques B de Kok. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacques B de Kok. The network helps show where Jacques B de Kok may publish in the future.
Co-authorship network of co-authors of Jacques B de Kok
This figure shows the co-authorship network connecting the top 25 collaborators of Jacques B de Kok. A scholar is included among the top collaborators of Jacques B de Kok based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacques B de Kok. Jacques B de Kok is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | The prognostic role of the STK15 T91A polymorphism and of STK15 mRNA expression in patients with urothelial cell carcinoma. | 4 |
| 3 | Simultaneous proteomic and genomic analysis of primary Ta urothelial cell carcinomas for the prediction of tumor recurrence. | 7 |
| 4 | 19 | |
| 5 | 31 | |
| 6 | 23 | |
| 7 | 6 | |
| 8 | 471 | |
| 9 | 34 | |
| 10 | DD3, a very sensitive and specific merker to detect prostate tumors. Reply to: Gandino O, Santulli M, Cardillo MR, Stigliano A, Toscano V. Correspondence re: J.B. de Kok et al. | 2 |
| 11 | 28 | |
| 12 | Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. | 52 |
| 13 | 110 | |
| 14 | DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. | 478 |
| 15 | 2 | |
| 16 | 17 | |
| 17 | 62 | |
| 18 | Real-time hTERT quantification: a promising telomerase-associated tumor marker. | 17 |
| 19 | 53 | |
| 20 | 64 |
About Jacques B de Kok
Jacques B de Kok is a scholar working on Biotechnology, Physiology and Surgery, having authored 24 papers that have together received 1.7k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (9 papers), Cancer Research and Treatments (5 papers) and Telomeres, Telomerase, and Senescence (5 papers). The work is most often cited by research in Cancer Research (530 citations), Molecular Biology (962 citations) and Pulmonary and Respiratory Medicine (362 citations). Jacques B de Kok has collaborated with scholars based in Netherlands, United States and Sweden. Frequent co-authors include Dorine W. Swinkels, Rian Roelofs, B. Giesendorf, Jack A. Schalken, Lambertus A. Kiemeney, Tilly Aalders, Paul N. Span, Daphne Hessels, Gerald W. Verhaegh and Jeroen L. A. Pennings. Their work appears in journals such as Cancer Research, International Journal of Cancer and Clinical Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.